Protalix Biotherap | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 17.85 M

Revenue: As of FY2025 Q3, the actual value is USD 17.85 M, missing the estimate of USD 17.87 M.

EPS: As of FY2025 Q3, the actual value is USD 0.03.

EBIT: As of FY2025 Q3, the actual value is USD 2.023 M.

Total Revenue: $43.6 million for the nine months ended September 30, 2025, compared to $35.2 million for the same period in 2024.
Revenue from Selling Goods: $43.1 million for the nine months ended September 30, 2025, compared to $34.8 million for the same period in 2024.
Revenue from License and R&D Services: $0.5 million for the nine months ended September 30, 2025, compared to $0.4 million for the same period in 2024.

Net Income (Loss): Net loss of $1.1 million for the nine months ended September 30, 2025, compared to a net loss of $3.6 million for the same period in 2024.
Operating Income (Loss): Operating loss of $0.8 million for the nine months ended September 30, 2025, compared to an operating loss of $3.3 million for the same period in 2024.
Research and Development Expenses: $13.9 million for the nine months ended September 30, 2025, compared to $8.8 million for the same period in 2024.
Selling, General and Administrative Expenses: $8.2 million for the nine months ended September 30, 2025, compared to $9.2 million for the same period in 2024.

Net Cash Used in Operating Activities: - $14.0 million for the nine months ended September 30, 2025, compared to net cash provided by operating activities of $4.7 million for the same period in 2024.
Net Cash Used in Investing Activities: - $1.3 million for the nine months ended September 30, 2025, compared to net cash provided by investing activities of $19.5 million for the same period in 2024.
Net Cash Provided by Financing Activities: $9.2 million for the nine months ended September 30, 2025, compared to net cash used in financing activities of $20.4 million for the same period in 2024.

Core Business Focus: Protalix BioTherapeutics, Inc. plans to continue its focus on developing treatments for rare and orphan diseases, leveraging its ProCellEx platform and PEGylation capabilities. The company is preparing for a phase 2 clinical trial of PRX-115 for the treatment of uncontrolled gout, expected to commence in the fourth quarter of 2025.
Non-Core Business: The company is exploring novel platform technologies and continuously evaluates potential strategic marketing partnerships and collaboration programs with biotechnology and pharmaceutical companies.
Priority: The company expects to incur significant expenditures due to research and development efforts and believes its cash and cash equivalents are sufficient to satisfy capital needs for at least 12 months from the date of the report.